|
Dabrafenib Clinical Trials
13 actively recruiting trials across 4 locations
▼ -1 trial since June 2026
Also known as: BRAF Inhibitor GSK2118436, DRB436, GSK-2118436, GSK-2118436A, GSK2118436 +2 more
Pipeline
Phase 1: 2Phase 2: 8Phase 3: 1Phase 4: 1
Top Sponsors
- Tianjin Medical University Second Hospital1
- Tianjin Medical University Cancer Institute and Hospital1
- The Netherlands Cancer Institute1
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University1
- Rina Plattner1
Indications
- Cancer13
- Solid Tumor3
- Lung Cancer2
- Ipilimumab N011
- Dabrafenib1
Other9 trials
Anchorage, Alaska1 trial
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Anchorage Associates in Radiation Medicine
Phase 3
Scottsdale, Arizona1 trial
Dabrafenib and/or Trametinib Rollover Study
Honor Health Research Institute
Phase 4
Duarte, California1 trial
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
City of Hope Medical Center
Phase 1
Iowa City, Iowa1 trial
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
University of Iowa
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.